Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Stock Forecast

Stock Price Forecast

The 24 analysts that cover Vertex Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $526.79, which forecasts a 6.03% increase in the stock price over the next year. The lowest target is $414 and the highest is $607.

Price Target: $526.79 (+6.03%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$414	$526.79	$541	$607
Change	-16.67%	+6.03%	+8.89%	+22.17%

Analyst Ratings

The average analyst rating for Vertex Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Sep '25	Oct '25	Nov '25	Dec '25	Jan '26	Feb '26
Strong Buy	8	8	8	7	8	8
Buy	8	8	8	9	12	12
Hold	9	10	10	8	7	7
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	25	26	26	24	27	27

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Whitney Ijem Canaccord Genuity	Canaccord Genuity	Hold Maintains $411 → $441	Hold	Maintains	$411 → $441	-11.24%	Feb 17, 2026
Eliana Merle Barclays	Barclays	Buy Maintains $606 → $607	Buy	Maintains	$606 → $607	+22.17%	Feb 17, 2026
Andrew S. Fein HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $518 → $591	Strong Buy	Maintains	$518 → $591	+18.95%	Feb 17, 2026
Greg Harrison Scotiabank	Scotiabank	Hold Maintains $495 → $558	Hold	Maintains	$495 → $558	+12.31%	Feb 13, 2026
Brian Abrahams RBC Capital	RBC Capital	Buy Maintains $546 → $541	Buy	Maintains	$546 → $541	+8.89%	Feb 13, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

13.33B

Increased by 11.10%

from 12.00B

Revenue Next Year

14.70B

Increased by 10.23%

from 13.33B

EPS This Year

20.39

Increased by 33.08%

from 15.32

EPS Next Year

22.88

Increased by 12.24%

from 20.39

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	7.57B	8.93B	9.87B	11.02B	12.00B	13.33B	14.70B
Revenue Growth	22.06%	17.91%	10.51%	11.66%	8.90%	11.10%	10.23%
EPS	9.01	12.82	13.89	-2.08	15.32	20.39	22.88
EPS Growth	-12.44%	42.29%	8.35%	-	-	33.08%	12.24%
Forward PE	-	-	-	-	-	24.37	21.71
No. Analysts	-	-	-	-	-	33	25

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027	2028	2029	2030
High	14.2B	17.2B
Avg	13.3B	14.7B
Low	12.1B	12.7B

Revenue Growth

Revenue Growth	2026	2027	2028	2029	2030
High	18.2%	29.0%
Avg	11.1%	10.2%
Low	0.5%	-4.7%

EPS Forecast

EPS	2026	2027	2028	2029	2030
High	23.43	29.61
Avg	20.39	22.88
Low	17.79	18.33

EPS Growth

EPS Growth	2026	2027	2028	2029	2030
High	52.9%	45.2%
Avg	33.1%	12.2%
Low	16.1%	-10.1%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.